Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating VELCADE and dexamethasone induction before transplant in previously untreated multiple myeloma
2005-000186-19Phase 2Active
- Sponsor
- PETHEMA
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by PETHEMA. Primary endpoint: Overall response rate to Velcadexa. Started May 2006; status: active.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-000186-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000186-19.